These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
849 related articles for article (PubMed ID: 26837745)
1. From C-Reactive Protein to Interleukin-6 to Interleukin-1: Moving Upstream To Identify Novel Targets for Atheroprotection. Ridker PM Circ Res; 2016 Jan; 118(1):145-56. PubMed ID: 26837745 [TBL] [Abstract][Full Text] [Related]
3. Anticytokine Agents: Targeting Interleukin Signaling Pathways for the Treatment of Atherothrombosis. Ridker PM Circ Res; 2019 Feb; 124(3):437-450. PubMed ID: 30702995 [TBL] [Abstract][Full Text] [Related]
4. High-sensitivity C-reactive protein and atherosclerotic disease: from improved risk prediction to risk-guided therapy. Koenig W Int J Cardiol; 2013 Oct; 168(6):5126-34. PubMed ID: 23978367 [TBL] [Abstract][Full Text] [Related]
5. Effects of interleukin-1β inhibition with canakinumab on hemoglobin A1c, lipids, C-reactive protein, interleukin-6, and fibrinogen: a phase IIb randomized, placebo-controlled trial. Ridker PM; Howard CP; Walter V; Everett B; Libby P; Hensen J; Thuren T; Circulation; 2012 Dec; 126(23):2739-48. PubMed ID: 23129601 [TBL] [Abstract][Full Text] [Related]
6. Comparison of interleukin-6, C-reactive protein, and low-density lipoprotein cholesterol as biomarkers of residual risk in contemporary practice: secondary analyses from the Cardiovascular Inflammation Reduction Trial. Ridker PM; MacFadyen JG; Glynn RJ; Bradwin G; Hasan AA; Rifai N Eur Heart J; 2020 Aug; 41(31):2952-2961. PubMed ID: 32221587 [TBL] [Abstract][Full Text] [Related]
7. Atherothrombosis and the NLRP3 inflammasome - endogenous mechanisms of inhibition. Satish M; Agrawal DK Transl Res; 2020 Jan; 215():75-85. PubMed ID: 31469975 [TBL] [Abstract][Full Text] [Related]
8. Adjunctive canakinumab reduces peripheral inflammation markers and improves positive symptoms in people with schizophrenia and inflammation: A randomized control trial. Weickert TW; Jacomb I; Lenroot R; Lappin J; Weinberg D; Brooks WS; Brown D; Pellen D; Kindler J; Mohan A; Wakefield D; Lloyd AR; Stanton C; O'Donnell M; Liu D; Galletly C; Shannon Weickert C Brain Behav Immun; 2024 Jan; 115():191-200. PubMed ID: 37848096 [TBL] [Abstract][Full Text] [Related]
9. NLRP3 Inflammasome and the IL-1 Pathway in Atherosclerosis. Grebe A; Hoss F; Latz E Circ Res; 2018 Jun; 122(12):1722-1740. PubMed ID: 29880500 [TBL] [Abstract][Full Text] [Related]
10. Interleukin-1 and the Inflammasome as Therapeutic Targets in Cardiovascular Disease. Abbate A; Toldo S; Marchetti C; Kron J; Van Tassell BW; Dinarello CA Circ Res; 2020 Apr; 126(9):1260-1280. PubMed ID: 32324502 [TBL] [Abstract][Full Text] [Related]
11. Effect of interleukin-1β inhibition with canakinumab on incident lung cancer in patients with atherosclerosis: exploratory results from a randomised, double-blind, placebo-controlled trial. Ridker PM; MacFadyen JG; Thuren T; Everett BM; Libby P; Glynn RJ; Lancet; 2017 Oct; 390(10105):1833-1842. PubMed ID: 28855077 [TBL] [Abstract][Full Text] [Related]
12. Closing the loop on inflammation and atherothrombosis: why perform the CIRT and CANTOS trials? Ridker PM Trans Am Clin Climatol Assoc; 2013; 124():174-90. PubMed ID: 23874021 [TBL] [Abstract][Full Text] [Related]
13. Interleukin-1β inhibition and the prevention of recurrent cardiovascular events: rationale and design of the Canakinumab Anti-inflammatory Thrombosis Outcomes Study (CANTOS). Ridker PM; Thuren T; Zalewski A; Libby P Am Heart J; 2011 Oct; 162(4):597-605. PubMed ID: 21982649 [TBL] [Abstract][Full Text] [Related]
19. Why Colchicine Should Be Considered for Secondary Prevention of Atherosclerosis: An Overview. Nidorf SM; Thompson PL Clin Ther; 2019 Jan; 41(1):41-48. PubMed ID: 30591286 [TBL] [Abstract][Full Text] [Related]